Verteporfin

维替泊芬

Report date: 2023/03/21 10:40:14
NME

Base Information

Drug NameVerteporfin
Drug Alias NameVerteporfinum维替泊芳威特伯芬EverteporfineVerteporfina +[13] 
ClassificationSmall molecules > Heterocyclic drugs
Mechanisms of ActionPhotosensitizers
TargetsNot applicable
Therapy Area/IndicationsMetastatic breast cancerSkin MelanomaSolid tumours +[14] 
Global Approved IndicationsChoroidal NeovascularizationMacular DegenerationMyopia, Degenerative +[5] 
Approved Indications in ChinaN/A
Original Approved Country/TerritorySwitzerland
Original Approved Date1999/12/16
Country/TerritoryCanadaUnited StatesSweden +[9] 
CombinationsNo
Global Highest StatusApproved
Highest Status in ChinaN/A
Originator CompaniesNovartis Pharma Ag
China Registration ClassN/A

Develop Information

Active CompaniesSpectracure AbNovartis Pharmaceuticals (Hk) LtdBausch + Lomb Ireland Ltd +[9] 
Inactive CompaniesQlt IncRogers Sciences Inc
Active IndicationsSolid tumoursCicatrixChoroidal Neovascularization +[10] 
Inactive IndicationsMetastatic breast cancerSkin MelanomaCarcinoma, Basal Cell +[4] 

Other Information

ATC CodeS01LA01
Related LinksWikipediaDrugBankKEGG